Research programme: NAD(P)H oxidase inhibitors - vasopharm BIOTECH
Alternative Names: VAS 2870Latest Information Update: 04 Nov 2017
At a glance
- Originator vasopharm BIOTECH
- Class
- Mechanism of Action NADH oxidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Peripheral arterial occlusive disorders
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Peripheral-arterial-occlusive-disorders in Germany
- 31 May 2011 Preclinical development is ongoing in Germany
- 16 Feb 2007 VAS 2870 is still in active development